BTC has broadened its distribution partnership with Arna

BTC Health (ASX: BTC) has announced that its wholly owned investee company, BTC Pharma, has amended its License and Distribution Agreement for Bronchitol and Aridol, strengthening its partnership with Arna Pharma.

Under the revised terms, BTC Pharma has assigned Singapore and Malaysia distribution rights to Arna Pharma, receiving a single-digit royalty on sales for three years. In return, BTC Pharma has secured an indefinite license to distribute the products in Australia and New Zealand. Additionally, Arna Pharma has granted BTC Pharma the first right of refusal to commercialize its specialty pharmaceutical pipeline in Australia and New Zealand. Dr Richard Treagus, Executive Chairman of BTC Health, highlighted the collaboration’s potential to bring innovative treatments to Australian patients.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com